Adaptive high-precision radiation for abdominopelvic lymph node oligometastases
Official title: Adaptive Fractionation in Online Adaptive Stereotactic Radiotherapy for Abdominopelvic Lymph Node Oligometastases
Run by Erasmus Medical Center · NCT07415356 · Data updated 2026-11-12
This trial will try giving adapted high-dose, fewer-session targeted radiation (online adaptive SBRT) to adults with up to five abdominal or pelvic lymph node metastases to shorten treatment time while protecting nearby organs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rotterdam, South Holland) |
| Status | Recruiting |
| Started | February 27, 2025 |
| Main results expected | February 5, 2026 |
| Study ends | January 1, 2028 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07415356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with abdominal or pelvic lymph node recurrences from solid tumors, no more than five metastases in up to two organs, a controlled primary site, recent PET/CT imaging, no prior radiotherapy to the same field, and who can give informed consent.
✕Probably not a fit
Patients with prior radiotherapy to the same area, widespread metastatic disease, an uncontrolled primary tumor, or serious comorbidities that limit safe treatment may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional approach uses online adaptive stereotactic body radiotherapy (SBRT) that adjusts the daily treatment plan to the patient's anatomy to better spare nearby radiosensitive organs such as the bowel. To counter the longer delivery time required for adaptive planning, the protocol tests increasing the dose per fraction and reducing the number of fractions (adaptive fractionation). Eligible patients have up to five metastatic lesions in no more than two organs, a controlled primary tumor, and recent PET or CT imaging. Treatments are delivered at Erasmus MC with close imaging-based planning and follow-up to monitor local control and toxicity.
Why it matters
Potential benefit: If successful, this approach could shorten treatment visits while maintaining high tumor control and reducing radiation exposure to nearby organs, potentially delaying systemic therapy and its side effects.
How similar studies have gone: Conventional SBRT for oligometastases has shown high local control and improved disease-free survival in prior studies, but using online adaptive SBRT with increased per-fraction doses to shorten sessions is a newer approach with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients with abdominal and/or pelvic lymph node recurrences of solid tumors. * No more than 5 metastatic lesions in no more than 2 organs and a controlled primary tumor site. * Diagnostic imaging includes at least a PET scan or CT thorax/abdomen, of which one is not older than 4 weeks at the time of referral for SBRT. * Primary tumor must be treated at least 4 months before the diagnosis of metastasis. * Patients must be 18 years or older. * Written informed consent. Exclusion criteria: * Prior radiotherapy in the same field. * Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Where it's running
-
Erasmus MC
Rotterdam, South Holland, Netherlands Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SYMmetric Valve expansion to reduce hypoattenuated leaflet thickening after balloon-expandable TAVI
This trial tests whether the Double-TAP post-dilatation strategy can reduce HALT and improve valve function in patients 70 or older undergoing balloon-expandable TAVI.
-
External warming to help septic patients without fever
We’re testing whether warming the body externally can help people with sepsis who don’t have a fever.
-
Personalized AI Education Avatar for cancer treatment information
A digital avatar using AI-delivered educational videos helps adults starting new cancer treatments learn about their plan and side effects, with patient-friendly guidance and nurse support as needed.
-
Turbine-based CO2 Insufflator in Pediatric Laparoscopy
A new turbine-powered CO2 insufflator is being tested in children to see if it can maintain steadier abdominal pressures during laparoscopic surgery.
-
Guideline Adherence in HFrEF: See If Mirror Information Helps Doctors and Patients Follow GDMT
This study tests whether showing doctors, or both doctors and patients, mirror information about how well guideline-directed medical therapy is being used in heart failure with reduced ejection fraction.
-
Mild heat therapy added to standard treatment for locally advanced head and neck cancer
This early-stage trial tests whether mild hyperthermia can be safely added to standard radiotherapy with or without chemotherapy for locally advanced head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.